XBiotech Inc. (XBIT)
Nasdaq · Healthcare · Biotechnology
$2.18−0.46%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $66.5M
- Forward P/E
- 16.8
- 52-week range
- $2.09 – $3.44
- 52-week change
- −17.67%
- EPS (trailing)
- −$1.48
Fiscal year to Dec 2025
- Net income
- −$45.5M
- Diluted EPS
- −$1.49
- Free cash flow
- −$40.2M
From the company’s annual report on SEC EDGAR.
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Headquarters: Austin, United States · 87 employees · xbiotech.com